Summary
Global Markets Direct’s, ‘Kidney Transplantation - Pipeline Review, H1 2016’, provides an overview of the Kidney Transplantation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Kidney Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplantation and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
- The report reviews pipeline therapeutics for Kidney Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Kidney Transplantation therapeutics and enlists all their major and minor projects
- The report assesses Kidney Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Kidney Transplantation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alexion Pharmaceuticals, Inc.
Amgen Inc.
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Astellas Pharma Inc.
Bio-inRen
Catalyst Biosciences, Inc.
Corline Biomedical AB
CSL Limited
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Effimune SAS
FibroGen, Inc.
GlaxoSmithKline Plc
Grifols, S.A.
Hansa Medical AB
Kyowa Hakko Kirin Co., Ltd.
Mabtech Limited
Noorik Biopharmaceuticals AG
Novartis AG
Opsona Therapeutics Limited
Pharming Group N.V.
Prolong Pharmaceuticals, LLC
Quark Pharmaceuticals, Inc.
Shire Plc
t-cell Europe GmbH
Tiziana Life Sciences Plc
Zyrnat Biotherapeutics SL
'
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Kidney Transplantation Overview 11
Therapeutics Development 12
Pipeline Products for Kidney Transplantation – Overview 12
Pipeline Products for Kidney Transplantation – Comparative Analysis 13
Kidney Transplantation – Therapeutics under Development by Companies 14
Kidney Transplantation – Therapeutics under Investigation by Universities/Institutes 16
Kidney Transplantation – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Kidney Transplantation – Products under Development by Companies 21
Kidney Transplantation – Products under Investigation by Universities/Institutes 23
Kidney Transplantation – Companies Involved in Therapeutics Development 24
Alexion Pharmaceuticals, Inc. 24
Amgen Inc. 25
Amyndas Pharmaceuticals LLC 26
Angion Biomedica Corp. 27
Astellas Pharma Inc. 28
Bio-inRen 29
Catalyst Biosciences, Inc. 30
Corline Biomedical AB 31
CSL Limited 32
Digna Biotech, S.L. 33
Dompe Farmaceutici S.p.A. 34
Effimune SAS 35
FibroGen, Inc. 36
GlaxoSmithKline Plc 37
Grifols, S.A. 38
Hansa Medical AB 39
Kyowa Hakko Kirin Co., Ltd. 40
Mabtech Limited 41
Noorik Biopharmaceuticals AG 42
Novartis AG 43
Opsona Therapeutics Limited 44
Pharming Group N.V. 45
Prolong Pharmaceuticals, LLC 46
Quark Pharmaceuticals, Inc. 47
Shire Plc 48
t-cell Europe GmbH 49
Tiziana Life Sciences Plc 50
Zyrnat Biotherapeutics SL 51
Kidney Transplantation – Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
albumin (human) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
AMY-101 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AS-2521780 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
basiliximab biobetter - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BB-3 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
belimumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
bleselumab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
BRN-1889 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
C1 esterase inhibitor (human) - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
C1 esterase inhibitor (human) - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
C1 esterase inhibitor (recombinant) - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Cardiotrophin-1 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
carfilzomib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CB-2782 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Cellular Immunotherapy for Kidney Transplant - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Cellular Immunotherapy for Kidney Transplantation - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
CFZ-533 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
eculizumab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
EFFI-7H - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
FCR-001 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
FG-4497 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
foralumab - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
FR-104 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
FX-06 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
MRX-109 - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
N-003 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
OPN-305 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
QPI-1002 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Renaparin - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
reparixin - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Sanguinate - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
TNT-009 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ZY-11 - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Kidney Transplantation – Recent Pipeline Updates 130
Kidney Transplantation - Dormant Projects 166
Kidney Transplantation – Discontinued Products 169
Kidney Transplantation – Product Development Milestones 170
Featured News & Press Releases 170
Apr 04, 2016: FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation 170
Mar 11, 2016: Study results presented in New England Journal of Medicine strengthen Hansa Medical belief in the potential of IdeS 170
Dec 07, 2015: True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease Supporting Patient Profiles for TNT009 Phase 1b Study 171
Nov 13, 2015: Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies 171
Nov 10, 2015: Data showing that IdeS can silence memory B-cells published in Journal of Immunology 172
Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials 172
Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants 172
Sep 15, 2015: Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015 173
Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS 173
Appendix 175
Methodology 175
Coverage 175
Secondary Research 175
Primary Research 175
Expert Panel Validation 175
Contact Us 175
Disclaimer 176
List of Tables
Number of Products under Development for Kidney Transplantation, H1 2016 12
Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Kidney Transplantation – Pipeline by Alexion Pharmaceuticals, Inc., H1 2016 24
Kidney Transplantation – Pipeline by Amgen Inc., H1 2016 25
Kidney Transplantation – Pipeline by Amyndas Pharmaceuticals LLC, H1 2016 26
Kidney Transplantation – Pipeline by Angion Biomedica Corp., H1 2016 27
Kidney Transplantation – Pipeline by Astellas Pharma Inc., H1 2016 28
Kidney Transplantation – Pipeline by Bio-inRen, H1 2016 29
Kidney Transplantation – Pipeline by Catalyst Biosciences, Inc., H1 2016 30
Kidney Transplantation – Pipeline by Corline Biomedical AB, H1 2016 31
Kidney Transplantation – Pipeline by CSL Limited, H1 2016 32
Kidney Transplantation – Pipeline by Digna Biotech, S.L., H1 2016 33
Kidney Transplantation – Pipeline by Dompe Farmaceutici S.p.A., H1 2016 34
Kidney Transplantation – Pipeline by Effimune SAS, H1 2016 35
Kidney Transplantation – Pipeline by FibroGen, Inc., H1 2016 36
Kidney Transplantation – Pipeline by GlaxoSmithKline Plc, H1 2016 37
Kidney Transplantation – Pipeline by Grifols, S.A., H1 2016 38
Kidney Transplantation – Pipeline by Hansa Medical AB, H1 2016 39
Kidney Transplantation – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 40
Kidney Transplantation – Pipeline by Mabtech Limited, H1 2016 41
Kidney Transplantation – Pipeline by Noorik Biopharmaceuticals AG, H1 2016 42
Kidney Transplantation – Pipeline by Novartis AG, H1 2016 43
Kidney Transplantation – Pipeline by Opsona Therapeutics Limited, H1 2016 44
Kidney Transplantation – Pipeline by Pharming Group N.V., H1 2016 45
Kidney Transplantation – Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 46
Kidney Transplantation – Pipeline by Quark Pharmaceuticals, Inc., H1 2016 47
Kidney Transplantation – Pipeline by Shire Plc, H1 2016 48
Kidney Transplantation – Pipeline by t-cell Europe GmbH, H1 2016 49
Kidney Transplantation – Pipeline by Tiziana Life Sciences Plc, H1 2016 50
Kidney Transplantation – Pipeline by Zyrnat Biotherapeutics SL, H1 2016 51
Assessment by Monotherapy Products, H1 2016 52
Number of Products by Stage and Target, H1 2016 54
Number of Products by Stage and Mechanism of Action, H1 2016 56
Number of Products by Stage and Route of Administration, H1 2016 58
Number of Products by Stage and Molecule Type, H1 2016 60
Kidney Transplantation Therapeutics – Recent Pipeline Updates, H1 2016 130
Kidney Transplantation – Dormant Projects, H1 2016 166
Kidney Transplantation – Dormant Projects (Contd..1), H1 2016 167
Kidney Transplantation – Dormant Projects (Contd..2), H1 2016 168
Kidney Transplantation – Discontinued Products, H1 2016 169
List of Figures
Number of Products under Development for Kidney Transplantation, H1 2016 12
Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 52
Number of Products by Top 10 Targets, H1 2016 53
Number of Products by Stage and Top 10 Targets, H1 2016 53
Number of Products by Top 10 Mechanism of Actions, H1 2016 55
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 55
Number of Products by Routes of Administration, H1 2016 57
Number of Products by Stage and Routes of Administration, H1 2016 57
Number of Products by Top 10 Molecule Types, H1 2016 59
Number of Products by Stage and Top 10 Molecule Types, H1 2016 59
